UK healthcare products regulator in talks with Google/DeepMind over its Streams app

techcrunch | May 18, 2016

An app being made by DeepMind, the Google-owned AI company, working in collaboration with the NHS Royal Free Trust in London and being used to help identify hospital patients who might be at risk of acute kidney disease (AKI) is not currently in use, TechCrunch has learned...

Spotlight

The health landscape is changing dramatically. Total healthcare spending in the United States comprises around 20 percent of the GDP, yet for all that spending, our nation is not getting healthier. With declining health trends, an aging population, and the growing prevalence of chronic conditions,2  healthcare costs continue to escalate for employers and employees.

Spotlight

The health landscape is changing dramatically. Total healthcare spending in the United States comprises around 20 percent of the GDP, yet for all that spending, our nation is not getting healthier. With declining health trends, an aging population, and the growing prevalence of chronic conditions,2  healthcare costs continue to escalate for employers and employees.

Related News

HEALTH TECHNOLOGY

Axonics® Expands Sacral Neuromodulation Intellectual Property Portfolio

Axonics, Inc. | August 18, 2022

Axonics, Inc. a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced that in the last twelve months, the United States Patent and Trademark Office has granted eight patents and allowed four patent applications related to the company’s sacral neuromodulation technology. The patents and allowed applications are part of Axonics’ patent portfolio and represents technology internally developed by the company covering a range of subject matter that includes the Axonics external trial system, tined lead, implantable neurostimulator, clinician programmer, wireless charging system and patient remote control. “Axonics is committed to developing best-in-class technology to serve the unmet needs of the millions of adults suffering from incontinence. The volume, subject matter diversity, and breadth of these patents demonstrate the investment in innovation that Axonics continues to make in sacral neuromodulation technology,” Raymond W. Cohen, chief executive officer About Axonics Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas. Axonics sacral neuromodulation (SNM) systems provide adults suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence (SUI). Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 29 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries.

Read More

HEALTH TECHNOLOGY

TribeHealth Selects Engooden Health to Transform Care Delivery Through Chronic Disease Management

Engooden | August 26, 2022

Engooden Health, a company redefining chronic disease management announced a partnership with TribeHealth, a strategic care management organization. The collaboration enables TribeHealth to offer its partners and their patients chronic disease management services through Engooden’s scalable, technology-enhanced solution. TribeHealth partners with health systems to serve as both a trusted advisor and tactical partner to help increase revenue, improve quality of care, and enhance the patient experience. A leader in working to achieve health equity and improve access to care, TribeHealth offers insights into patient populations and specific programs that best support those populations. “At TribeHealth, we are committed to transforming care delivery for the betterment of our healthcare system and all patients, and Engooden is equally committed to this cause,” said Lyndsey Lord, Co-founder and COO of TribeHealth. “Engooden has a proven and effective, trust-based model for helping patients manage their chronic conditions with the expertise of their care navigators. We want to help connect as many people as possible to these resources at the appropriate time.” Engooden’s chronic disease management platform is a proven, scalable solution for providers, health systems, and payers. Their proprietary technology automatically surfaces actionable insights to its care navigators, allowing them to intervene with the right patients at the right time. Care navigators help bridge care gaps for tens of thousands of patients through consistent, trust-based engagement. The personalized service is popular with patients, with an 88% annual program retention rate. Engooden Health partners with healthcare organizations of all types and sizes, bringing critical chronic disease management services to everyone from traditional fee-for-service physicians to accountable care organizations federally qualified health centers (FQHC), rural health clinics and other value-based care organizations. “Engooden’s tech-enhanced chronic disease management services allow us to build trust with patients at scale, driving clinical and financial outcomes that can help organizations better perform in value-based care. This partnership combines our shared commitment to health equity and desire to transform healthcare delivery. Together, we can help organizations to provide more comprehensive, high-quality care.” Ryan Atwood, VP of Payer Relations and Regulatory Compliance at Engooden Health More than 133 million Americans are currently managing chronic diseases, many of whom would benefit greatly from this historically underutilized service. In an effort to increase utilization, Centers for Medicare & Medicaid Services recently increased reimbursement for chronic care management services, further validating the role CCM plays in improving patient health and quality of life while driving down costs across the healthcare spectrum from fee-for-service to risk-based programs. Chronic disease management services include education, coaching, and advocacy. Common patient success stories include results such as reduced HbA1c, weight loss, decreased blood pressure, mitigating symptoms of depression, and much more. TribeHealth and Engooden are partnering to immediately make this service more readily available to all patients who need it. About TribeHealth TribeHealth designs networks of people and technology to assist patients, providers, and payers achieve optimal health & cost outcomes. TribeHealth partners with leading healthcare organizations to support new and existing care delivery models while assisting with preventive engagement strategies aimed at successful population care. TribeHealth was formed in 2020 by a team of clinicians and health scientists to bring responsive care resources to as many people as possible. About Engooden Health Engooden Health is the only company to offer scalable chronic care management (CCM) services and technology for physicians, health systems, and payers to identify rising-risk and chronically ill patients and positively impact their health trajectories. Through technology-driven, personalized intervention by experienced and empathetic care navigators, Engooden connects with thousands of patients each month, addressing their barriers to care while helping its customers effectively manage population health and value-based care programs. Founded in 2016, Engooden Health is headquartered in Boston.

Read More

HEALTH TECHNOLOGY

Planet DDS Acquires QSIDental from NextGen Healthcare

Planet DDS | August 12, 2022

Planet DDS, the leading provider of cloud-based dental software, announced the acquisition of QSIDental from NextGen Healthcare, Inc. QSIDental offers cloud-based dental practice management software and has been a trusted clinical software partner to dental organizations for 40 years. This acquisition, including QSIDental Web®, reinforces the company’s commitment to cloud-based solutions as a way for dental practices to navigate and uncover new opportunities through unprecedented times in the industry. Planet DDS will actively support the needs of existing QSIDental customers, empowering their growth and success through industry-leading cloud solutions. “With rising costs and a difficult hiring environment, these are challenging times for dental practices. Planet DDS is committed to helping our customers to be more efficient and reduce costs while delivering better patient care. This acquisition enhances our ability to deliver top-rated cloud-based software to more dental practices across North America, and we are excited to welcome QSIDental team members and customers into the Planet DDS family.” Eric Giesecke, CEO of Planet DDS Planet DDS and QSIDental share similar philosophies on the use of technology to deliver more efficient workflows for dental practices, maximize quality of care, and enhance the patient experience. About Planet DDS Planet DDS is the leading provider of cloud-enabled dental software solutions serving over 10,000 practices in North America with over 60,000 users. The company delivers a complete platform of solutions for dental practices including Denticon Practice Management, Apteryx XVWeb Digital Imaging, and Legwork Patient Relationship Management. Planet DDS is committed to creating value for its dental practice clients by solving the most urgent challenges facing today’s dental practices in North America.

Read More